Overview

A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Protocol HECT00306 aims to determine clinically appropriate doses of Hectorol (doxercalciferol capsules) when converting from Zemplar (paricalcitol injection) for the treatment of secondary hyperparathyroidism in Stage 5 chronic kidney disease on hemodialysis.
Phase:
Phase 4
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Treatments:
1 alpha-hydroxyergocalciferol
Ergocalciferols